
Johnson & Johnson
JNJHealthcare|Drug Manufacturers - General|US
$276.22
+3.90 (+1.43%)
DCF Value
$295.64
Graham Number
$70.20
Cash / Share
$7.04
Financials
Financial Snapshot
Market Cap
$664.95B
Enterprise Value
$692.69B
Revenue (TTM)
$99.33B
Net Income (TTM)
$16.09B
Cash & Investments
$17.23B
Net Cash
-$27.42B
Free Cash Flow (TTM)
$20.59B
Operating CF (TTM)
$26.16B
Debt/Equity
0.55
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $41.91B | $18.30B | $19.69B | $19.29B | $25.18B | $31.61B | $22.28B | $22.93B | $24.52B | $20.10B | $17.23B | |
| Operating Cash Flow | $18.77B | $21.06B | $22.20B | $23.42B | $23.54B | $23.41B | $21.19B | $22.79B | $24.27B | $24.53B | $26.16B | |
| Free Cash Flow | $15.54B | $17.78B | $18.53B | $19.92B | $20.19B | $19.76B | $17.18B | $18.25B | $19.84B | $19.70B | $20.59B | |
| Capital Expenditure | -$3.23B | -$3.28B | -$3.67B | -$3.50B | -$3.35B | -$3.65B | -$4.01B | -$4.54B | -$4.42B | -$4.83B | -$5.57B | |
| Financing Cash Flow | -$8.55B | -$7.67B | -$18.51B | -$18.02B | -$6.12B | -$14.05B | -$8.87B | -$15.82B | -$3.13B | -$5.54B | -$18.15B |
R&D Spending
R&D (TTM)
$16.08B
R&D Intensity
16.2%
R&D Growth vs Prior
+9.7%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.89B | $76.45B | $81.58B | $82.06B | $82.58B | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B | $99.33B | |
| R&D Expense | $9.14B | $10.59B | $10.78B | $11.36B | $12.34B | $14.28B | $14.13B | $15.09B | $17.23B | $14.66B | $16.08B | |
| R&D % of Revenue | 12.7% | 13.9% | 13.2% | 13.8% | 14.9% | 18.1% | 17.7% | 17.7% | 19.4% | 15.6% | 16.2% | |
| SG&A | $20.07B | $21.52B | $22.54B | $22.18B | $22.08B | $20.12B | $20.25B | $20.11B | $21.97B | $23.68B | $25.50B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71.89B | $76.45B | $81.58B | $82.06B | $82.58B | $78.74B | $79.99B | $85.16B | $88.82B | $94.19B | $99.33B | |
| Cost of Revenue | $21.79B | $25.44B | $27.09B | $27.56B | $28.43B | $23.40B | $24.60B | $26.55B | $27.47B | $30.26B | $30.98B | |
| Gross Profit | $50.10B | $51.01B | $54.49B | $54.50B | $54.16B | $55.34B | $55.39B | $58.61B | $61.35B | $63.94B | $68.35B | |
| R&D | $9.14B | $10.59B | $10.78B | $11.36B | $12.34B | $14.28B | $14.13B | $15.09B | $17.23B | $14.66B | $16.08B | |
| SG&A | $20.07B | $21.52B | $22.54B | $22.18B | $22.08B | $20.12B | $20.25B | $20.11B | $21.97B | $23.68B | $25.50B | |
| Operating Income | $20.89B | $18.90B | $21.18B | $20.97B | $19.73B | $20.94B | $21.01B | $23.41B | $22.15B | $25.60B | $25.52B | |
| Interest Expense | $726.0M | $934.0M | $1.00B | $318.0M | $201.0M | $183.0M | $276.0M | $772.0M | $755.0M | $971.0M | $798.0M | |
| Pretax Income | $19.80B | $17.67B | $18.00B | $17.33B | $16.50B | $19.18B | $19.36B | $15.06B | $16.69B | $32.58B | $17.74B | |
| Net Income | $16.54B | $1.30B | $15.30B | $15.12B | $14.71B | $20.88B | $17.94B | $35.15B | $14.07B | $26.80B | $16.09B | |
| EPS (Diluted) | 5.93 | 0.47 | 5.61 | 5.63 | 5.51 | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 | 6.60 | |
| EBITDA | $24.28B | $24.25B | $25.93B | $24.66B | $23.93B | $26.75B | $26.61B | $23.32B | $24.78B | $41.05B | $30.81B | |
| Shares Out. (M) | 2788.90 | 2745.30 | 2728.70 | 2684.30 | 2670.70 | 2674.00 | 2663.90 | 2560.40 | 2429.40 | 2429.40 | 2448.60 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.97B | $17.82B | $18.11B | $17.30B | $13.98B | $14.49B | $12.89B | $21.86B | $24.11B | $19.71B | $16.91B | |
| Short-Term Investments | $22.93B | $472.0M | $1.58B | $1.98B | $11.20B | $17.12B | $9.39B | $1.07B | $417.0M | $393.0M | $318.0M | |
| Total Current Assets | $65.03B | $43.09B | $46.03B | $45.27B | $51.24B | $60.98B | $55.29B | $53.49B | $55.89B | $55.62B | $56.35B | |
| Total Assets | $141.21B | $157.30B | $152.95B | $157.73B | $174.89B | $182.02B | $187.38B | $167.56B | $180.10B | $199.21B | $197.43B | |
| Total Current Liabilities | $26.29B | $30.54B | $31.23B | $35.96B | $42.49B | $45.23B | $55.80B | $46.28B | $50.32B | $54.13B | $55.46B | |
| Long-Term Debt | $22.44B | $30.68B | $27.68B | $26.49B | $32.63B | $29.98B | $26.89B | $25.88B | $30.65B | $39.44B | $35.80B | |
| Total Liabilities | $70.79B | $97.14B | $93.20B | $98.26B | $111.62B | $108.00B | $110.57B | $98.78B | $108.61B | $117.67B | $115.90B | |
| Stockholders' Equity | $70.42B | $60.16B | $59.75B | $59.47B | $63.28B | $74.02B | $76.80B | $68.77B | $71.49B | $81.54B | $81.53B | |
| Retained Earnings | $110.55B | $101.79B | $106.22B | $110.66B | $113.89B | $123.06B | $128.34B | $153.84B | $155.79B | $168.98B | $168.36B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $18.77B | $21.06B | $22.20B | $23.42B | $23.54B | $23.41B | $21.19B | $22.79B | $24.27B | $24.53B | $26.16B | |
| Capital Expenditure | -$3.23B | -$3.28B | -$3.67B | -$3.50B | -$3.35B | -$3.65B | -$4.01B | -$4.54B | -$4.42B | -$4.83B | -$5.57B | |
| Free Cash Flow | $15.54B | $17.78B | $18.53B | $19.92B | $20.19B | $19.76B | $17.18B | $18.25B | $19.84B | $19.70B | $20.59B | |
| Investing Cash Flow | -$4.76B | -$14.87B | -$3.17B | -$6.19B | -$20.82B | -$8.68B | -$12.37B | $878.0M | -$18.60B | -$23.59B | -$9.34B | |
| Financing Cash Flow | -$8.55B | -$7.67B | -$18.51B | -$18.02B | -$6.12B | -$14.05B | -$8.87B | -$15.82B | -$3.13B | -$5.54B | -$18.15B | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.24B | $0.00 | $0.00 | $3.86B | |
| Repurchase of Stock | -$8.98B | -$6.36B | -$5.87B | -$6.75B | -$3.22B | -$3.46B | -$6.04B | -$5.05B | -$2.43B | -$5.95B | -$7.88B | |
| Net Debt Issuance | $7.88B | $6.75B | -$3.95B | -$2.88B | $7.09B | -$990.0M | $7.45B | -$2.73B | $10.05B | $9.64B | -$787.0M | |
| Stock Based Comp. | $878.0M | $962.0M | $978.0M | $977.0M | $1.00B | $1.14B | $1.14B | $1.16B | $1.18B | $1.35B | $1.42B | |
| Net Change in Cash | $5.24B | -$1.15B | $283.0M | -$802.0M | -$3.32B | $502.0M | -$360.0M | $7.73B | $2.25B | -$4.40B | -$1.32B |
Dilution Tracker
Shares Outstanding
2407M
5-Year Share Growth
-9.0%
Stock Issuance (TTM)
$3.86B
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2788.90 | 2745.30 | 2728.70 | 2684.30 | 2670.70 | 2674.00 | 2663.90 | 2560.40 | 2429.40 | 2429.40 | 2448.60 | |
| Change vs Prior % | — | -1.6% | -0.6% | -1.6% | -0.5% | 0.1% | -0.4% | -3.9% | -5.1% | 0.0% | 0.8% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.24B | $0.00 | $0.00 | $3.86B | |
| Stock Repurchase | -$8.98B | -$6.36B | -$5.87B | -$6.75B | -$3.22B | -$3.46B | -$6.04B | -$5.05B | -$2.43B | -$5.95B | -$7.88B | |
| Stock Based Comp. | $878.0M | $962.0M | $978.0M | $977.0M | $1.00B | $1.14B | $1.14B | $1.16B | $1.18B | $1.35B | $1.42B |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 69.7% | 66.7% | 66.8% | 66.4% | 65.6% | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% | 68.8% | |
| Operating Margin % | 29.1% | 24.7% | 26.0% | 25.6% | 23.9% | 26.6% | 26.3% | 27.5% | 24.9% | 27.2% | 25.7% | |
| Net Margin % | 23.0% | 1.7% | 18.8% | 18.4% | 17.8% | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% | 16.2% | |
| EBITDA Margin % | 33.8% | 31.7% | 31.8% | 30.0% | 29.0% | 34.0% | 33.3% | 27.4% | 27.9% | 43.6% | 31.0% | |
| FCF Margin % | 21.6% | 23.3% | 22.7% | 24.3% | 24.4% | 25.1% | 21.5% | 21.4% | 22.3% | 20.9% | 20.7% | |
| ROE % | 23.5% | 2.2% | 25.6% | 25.4% | 23.3% | 28.2% | 23.4% | 51.1% | 19.7% | 32.9% | 19.6% | |
| ROA % | 11.7% | 0.8% | 10.0% | 9.6% | 8.4% | 11.5% | 9.6% | 21.0% | 7.8% | 13.5% | 8.2% | |
| ROIC % | 14.6% | 1.1% | 14.5% | 14.9% | 13.0% | 13.8% | 12.3% | 16.6% | 13.8% | 13.7% | 15.4% | |
| R&D / Revenue % | 12.7% | 13.9% | 13.2% | 13.8% | 14.9% | 18.1% | 17.7% | 17.7% | 19.4% | 15.6% | 16.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.6% | 6.3% | 6.7% | 0.6% | 0.6% | -4.7% | 1.6% | 6.5% | 4.3% | 6.0% | |
| Gross Profit | 3.2% | 1.8% | 6.8% | 0.0% | -0.6% | 2.2% | 0.1% | 5.8% | 4.7% | 4.2% | |
| Operating Income | 14.2% | -9.5% | 12.1% | -1.0% | -5.9% | 6.1% | 0.3% | 11.4% | -5.4% | 15.6% | |
| Net Income | 7.3% | -92.1% | 1076.7% | -1.2% | -2.7% | 41.9% | -14.1% | 95.9% | -60.0% | 90.6% | |
| EPS (Diluted) | 8.2% | -92.1% | 1093.6% | 0.4% | -2.1% | 41.7% | -13.8% | 103.9% | -57.8% | 90.5% | |
| Operating Cash Flow | -2.7% | 12.2% | 5.4% | 5.5% | 0.5% | -0.5% | -9.5% | 7.5% | 6.5% | 1.1% | |
| Free Cash Flow | -1.7% | 14.4% | 4.2% | 7.5% | 1.4% | -2.1% | -13.0% | 6.2% | 8.7% | -0.7% | |
| R&D Expense | 1.1% | 15.9% | 1.7% | 5.4% | 8.7% | 15.7% | -1.0% | 6.7% | 14.2% | -14.9% | |
| SG&A Expense | -5.4% | 7.2% | 4.7% | -1.6% | -0.4% | -8.9% | 0.6% | -0.7% | 9.2% | 7.8% | |
| Total Assets | 5.8% | 11.4% | -2.8% | 3.1% | 10.9% | 4.1% | 2.9% | -10.6% | 7.5% | 10.6% | |
| Book Value / Share | 0.8% | -13.8% | 0.1% | 0.7% | 6.4% | 17.1% | 4.4% | -7.6% | 9.4% | 13.1% | |
| Debt | 36.6% | 27.5% | -11.9% | -9.1% | 27.3% | -4.3% | 17.5% | -26.0% | 24.9% | 30.8% | |
| Diluted Shares | -0.9% | -1.6% | -0.6% | -1.6% | -0.5% | 0.1% | -0.4% | -3.9% | -5.1% | 0.0% |
Valuation
P/E (TTM)41.88
10Y Low / Med / High11.29 / 24.54 / 291.08
P/S6.69
10Y Low / Med / High3.88 / 4.90 / 5.77
P/B8.29
10Y Low / Med / High4.43 / 6.09 / 6.51
EV/EBITDA22.48
10Y Low / Med / High12.97 / 16.15 / 18.36
EV/Revenue6.97
10Y Low / Med / High4.03 / 5.12 / 6.11
P/FCF32.29
10Y Low / Med / High17.39 / 21.08 / 26.87
Intrinsic Value Models (per share)
DCF Value
$295.64
Graham Number
$70.20
Cash / Share
$7.04
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 18.95 | 291.08 | 22.44 | 25.41 | 28.00 | 21.63 | 25.86 | 11.29 | 24.54 | 18.82 | 41.88 | |
| P/S Ratio | 4.34 | 4.90 | 4.21 | 4.68 | 4.99 | 5.73 | 5.77 | 4.66 | 3.88 | 5.35 | 6.69 | |
| P/B Ratio | 4.43 | 6.23 | 5.75 | 6.46 | 6.51 | 6.09 | 6.01 | 5.77 | 4.83 | 6.18 | 8.29 | |
| EV/EBITDA | 13.18 | 16.15 | 13.73 | 16.00 | 18.11 | 17.58 | 18.36 | 17.35 | 14.43 | 12.97 | 22.48 | |
| EV/Revenue | 4.45 | 5.12 | 4.36 | 4.81 | 5.25 | 5.97 | 6.11 | 4.75 | 4.03 | 5.65 | 6.97 |
Analyst Estimates & Quality
Altman Z-Score
5.56
Safe
Piotroski F-Score
7
Strong
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $101.22B | $107.76B | $116.59B |
| Net Income | $27.15B | $28.22B | $33.71B |
| EPS | $11.11 | $11.59 | $13.96 |
| # Analysts (EPS) | 11 | 12 | 5 |
Dividends
Dividend/Share (TTM)
$5.28
Dividend Yield
1.91%
Frequency
Quarterly
Next Payment
Dec 8, 2026
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Nov 24, 2026 | Dec 8, 2026 | $1.34 | Quarterly |
| Aug 25, 2026 | Sep 8, 2026 | $1.34 | Quarterly |
| May 26, 2026 | Jun 9, 2026 | $1.34 | Quarterly |
| Feb 24, 2026 | Mar 10, 2026 | $1.30 | Quarterly |
| Nov 25, 2025 | Dec 9, 2025 | $1.30 | Quarterly |
| Aug 26, 2025 | Sep 9, 2025 | $1.30 | Quarterly |
| May 27, 2025 | Jun 10, 2025 | $1.30 | Quarterly |
| Feb 18, 2025 | Mar 4, 2025 | $1.24 | Quarterly |
| Nov 26, 2024 | Dec 10, 2024 | $1.24 | Quarterly |
| Aug 27, 2024 | Sep 10, 2024 | $1.24 | Quarterly |
| May 20, 2024 | Jun 4, 2024 | $1.24 | Quarterly |
| Feb 16, 2024 | Mar 5, 2024 | $1.19 | Quarterly |
| Nov 20, 2023 | Dec 5, 2023 | $1.19 | Quarterly |
| Aug 25, 2023 | Sep 7, 2023 | $1.19 | Quarterly |
| May 22, 2023 | Jun 6, 2023 | $1.19 | Quarterly |
| Feb 17, 2023 | Mar 7, 2023 | $1.13 | Quarterly |
| Nov 21, 2022 | Dec 6, 2022 | $1.13 | Quarterly |
| Aug 22, 2022 | Sep 6, 2022 | $1.13 | Quarterly |
| May 23, 2022 | Jun 7, 2022 | $1.13 | Quarterly |
| Feb 18, 2022 | Mar 8, 2022 | $1.06 | Quarterly |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Consumer | $14.45B | $14.63B | $14.95B | — | — | — |
| Pharmaceutical | $45.17B | $52.08B | — | — | — | — |
| Medical Devices | $22.96B | $27.06B | — | — | — | — |
| Innovative Medicine | — | — | $52.56B | $54.76B | $56.96B | $60.40B |
| MedTech | — | — | $27.43B | $30.40B | $31.86B | $33.79B |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Europe | $18.98B | $23.59B | $23.45B | $20.41B | $20.21B | $21.54B |
| Asia-Pacific, Africa | $15.14B | $17.27B | $16.79B | $13.76B | $13.59B | $14.03B |
| UNITED STATES | $43.13B | $47.16B | $48.58B | $46.44B | $50.30B | $53.75B |
| Western Hemisphere, excluding U.S. | $5.33B | $5.75B | $6.13B | $4.55B | $4.71B | $4.88B |